Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

NATURE STRUCTURAL & MOLECULAR BIOLOGY. 2024-01; 
Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann  , Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss  , Amanda Chapman1 , Bernadette Tiberi1,2, Jennifer Dobrodziej1,3, John Corradi1 , Angela M. Cacace1 , David R. Langley & Miklós Békés
Products/Services Used Details Operation
Peptide Synthesis A gene encoding full-length KLHDC2 (Uniprot: Q9Y2U9) with an N-terminal GST-TEV-His tag was synthesized (Genscript) and cloned into a pFastBac vector./. Full-length EloB (Uniprot: Q15370) and EloC (Uniprot: Q15369) were synthesized (Genscript) and cloned into multiple cloning sites of pFastBacDual. /The final reactions included 3 nM 6×His-KLHDC2KD, 2 nM biotinylated SelK peptide (biotin-HLRGSPPPMAGG, Genscript), 12.5 µg mL–1 Anti-6×His Acceptor Beads (PerkinElmer), and 12.5 µg mL–1 Streptavidin Donor Beads (PerkinElmer) Get A Quote
Gene Synthesis Get A Quote

摘要

Targeted protein degradation (TPD) by PROTAC (proteolysis-targeting chimera) and molecular glue small molecules is an emerging therapeutic strategy. To expand the roster of E3 ligases that can be utilized for TPD, we describe the discovery and biochemical characterization of small-molecule ligands targeting the E3 ligase KLHDC2. Furthermore, we functionalize these KLHDC2-targeting ligands into KLHDC2-based BET-family and AR PROTAC degraders and demonstrate KLHDC2-dependent target-protein degradation. Additionally, we ofer insight into the assembly of the KLHDC2 E3 ligase complex. Using biochemical binding studies, X-ray crystallography and cryo-EM, we show that the KLHDC2 E3 ligase assembles into a dynamic tet... More

关键词

XML 地图